ADAR1 Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

ADAR1 Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$107K	Hold	35,000	–	–	0.01%	286
2025 Q4	$143K	Hold	35,000	–	–	0.01%	239
2025 Q3	$171K	Hold	35,000	–	–	0.02%	184
2025 Q2	$177K	Buy	35,000 +20,000	+133%	+$98.3K	0.03%	158
2025 Q1	$79.3K	Hold	15,000	–	–	0.01%	172
2024 Q4	$101K	Hold	15,000	–	–	0.02%	181
2024 Q3	$98.8K	Buy	+15,000	New	+$108K	0.02%	188

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ADAR1 Capital Management's RXRX Position: Q1 2026 in Review

ADAR1 Capital Management held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 35,000 shares worth $107K. The position accounts for 0.01% of the portfolio, ranked #286.

ADAR1 Capital Management first reported a position in RXRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $177K in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

ADAR1 Capital Management held 35,000 shares of Recursion Pharmaceuticals worth $107K as of Q1 2026.
ADAR1 Capital Management left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
Recursion Pharmaceuticals made up 0.01% of ADAR1 Capital Management's portfolio in Q1 2026, its #286 holding.
ADAR1 Capital Management first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
ADAR1 Capital Management's Recursion Pharmaceuticals position peaked at $177K in Q2 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.